The Quantellect read.As of Nov 19, 2026, 24 active firms cover Vertex Pharmaceuticals Inc: 20 rate it Buy or better, 3 sit at Neutral, and 1 rate it Sell or worse, a buy consensus. Targets span $350.00 to $665.00, a moderate spread. The average target of $562.00 sits 5% above the current $536.15. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $4.68 next quarter toward $19.92 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS24 active firms
Buy
Strong Buy00%
Buy2083%
Neutral313%
Sell14%
Strong Sell00%
Based on 24 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$562.00
+4.8% upside
Average target across 20 active firms as of Nov 19, 2026 vs $536.16 current
Highest Target$665.00
Average Target$562.00
Lowest Target$350.00
Detailed analyst forecasts for VRTX
Showing 1–21 of 21 named analysts shown · 24 active firms in the rating projection
As of Nov 19, 2026, 20 of 24 active firms rate VRTX a Buy (3 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
VRTX EPS & revenue forecast
EPS · NEXT QUARTER
$4.68
Range $4.18 – $5.28 · 8 analysts · +5% YoY
Next period, 8 analysts expect Vertex Pharmaceuticals Inc to earn $4.68 a share (range $4.18 – $5.28), versus $4.47 a year earlier. Full-year consensus is $18.14, growing to $19.92 the year after.
REVENUE · NEXT QUARTER
$3.4B
Range $3.1B – $3.7B · 8 analysts · +15% YoY
Revenue is expected to reach $3.4B (range $3.1B – $3.7B), +15.1% year-over-year. Full-year consensus is $13.3B, rising to $14.7B next year.
Top analysts covering Vertex Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VRTX.
#1
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$641.00+19.6% to target
Overall win rate
45%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #100
Buy
$570.00+6.3% to target
Overall win rate
54%
+ Follow
#3
Terence Flynn
Morgan Stanley · Rank #222
Buy
$660.00+23.1% to target
Overall win rate
36%
+ Follow
#4
Greg Harrison
Scotiabank · Rank #223
Neutral
$558.00+4.1% to target
Overall win rate
38%
+ Follow
#5
Debjit Chattopadhyay
Guggenheim · Rank #248
Buy
$546.00+1.8% to target
Overall win rate
39%
+ Follow
VRTX stock forecast FAQ
What is VRTX's average 12-month price target?+
The 20 active firms with a live target average $562.00 for Vertex Pharmaceuticals Inc over the next 12 months, ranging from a $665.00 high to a $350.00 low, as of Nov 19, 2026.
Is VRTX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 24 active firms as of Nov 19, 2026, 20 rate it Buy or Strong Buy, 3 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for VRTX?+
The Street-high target is $665.00 (Morgan Stanley), and the Street-low is $350.00 (Baird). The average of all 20 active-firm targets is $562.00.
How many active Wall Street firms cover VRTX?+
24 active firms have a recognized rating on Vertex Pharmaceuticals Inc as of Nov 19, 2026, and 20 active firms carry a live 12-month price target.
Who is the most accurate analyst covering VRTX?+
Among analysts who currently cover VRTX, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #73). Their current call is Buy with a $641.00 target.
What is Vertex Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $4.68 per share (range $4.18 – $5.28) across 8 analysts. Full-year EPS is projected at $18.14, rising to $19.92 the following year.
How much revenue is Vertex Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $3.4B (range $3.1B – $3.7B). Full-year revenue is projected at $13.3B, growing to $14.7B next year.
Have analysts been upgrading or downgrading VRTX lately?+
As of Nov 19, 2026, 20 of 24 active firms rate VRTX a Buy (3 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VRTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.